

INDUSTRY SYMPOSIA

Saturday, May 15

HALL 1.Alfama

14:00 - 15:30

Contrast Media Induced Nephropathy (CIN)

Chair: **P. Persson**, Berlin, Germany

Welcome

Introduction: What causes CIN?

P. Persson, Berlin, Germany

CIN: Critical review of the existing clinical evidence

M.A. Bettmann, New York, USA

Contrast induced alterations in regional kidney haemodynamics and oxygenation

S.N. Heyman, Jerusalem, Israel

How to avoid CIN: Guidelines from the European Society of Urogenital Radiology

H.S. Thomsen, Herlev, Denmark

General discussion, concluding remarks

organised by **BRACCO, GUERBET, SCHERING**

HALL 2.Baixa

14:00 - 15:30

Progress in Dialysis for diabetic patients Cardiovascular risk management

Chair: **F. Locatelli**, Lecco, Italy

Diabetes and dialysis: epidemiological aspects

F. Locatelli, Lecco, Italy

Blood pressure management: experiences gained through international clinical practices

J.M. Lopez Gomez, Madrid, Spain

C. Deziel, Montreal, Canada

C.W. McIntyre, Derby, United Kingdom

Hospital Research Funding: presentation of the awarded research projects

F. Locatelli, Lecco, Italy

organised by **HOSPAL**

HALL 4.Rossio

14:00 - 15:30

Cystatin C: improving diagnosis and monitoring in kidney disease

Chair: **R. Woitas**, Bonn, Germany

Cystatin C for GFR estimation - Introduction

R. Woitas, Bonn, Germany

Cystatin C for GFR estimation in children and adolescents

A. Bökenkamp, Amsterdam, The Netherlands

Measurement of renal function in liver disease

R. Woitas, Bonn, Germany

Clinical value of serum and urinary Cystatin C in acute renal failure

S. Herget-Rosenthal, Essen, Germany

organised by **DADE BEHRING**

HALL 1.Alfama

16:00 - 17:30

Enhancing renal anaemia management: new insights, best practice, future prospects

Chair: **W.H Hörl**, Vienna, Austria and **J.A. Rossert**, Paris, France

Welcome and introduction

W.H Hörl, Vienna, Austria

J.A. Rossert, Paris, France

Evaluating progress in the management of renal anaemia: results of the 2003 European Survey on Anaemia Management (ESAM)

C. Jacobs, Paris, France

A practical approach to improving renal anaemia therapy: clinical recommendations by the OPTA Working Group

Y. Vanrenterghem, Leuven, Belgium

Normalizing haemoglobin levels in early HD patients: lessons from an international randomized, double-blind, controlled trial

P.S. Parfrey, St. John's, Canada

Understanding antibody-mediated PRCA

K.-U. Eckardt, Erlangen, Germany

New horizons in the treatment of CKD: what does the future hold?

J. Knight, High Wycombe, United Kingdom

Panel discussion

organised by **ORTHO BIOTECH**

HALL 3.Lapa
16:00 - 17:30

Calcium-based phosphate binders in the treatment of patients with chronic kidney disease

Chair: **C. Nolan**, San Antonio, USA

Is induced calcium toxicity an avoidable complication of phosphate binding in renal failure?
E.A. Friedman, New York, USA

Comparison of calcium-based phosphate binders and sevelamer hydrochloride in the context of ERA-EDTA and K/DOQI Mineral Metabolism Guidelines
C. Nolan, San Antonio, USA

Risks of chronic metabolic acidosis in patients with chronic kidney disease
J.D. Kopple, Torrance, USA

Daily dialysis in the treatment of refractory hyperphosphataemia and hyperparathyroidism
J.C. Ayus, San Antonio, USA

organised by **BIOMUNE LIMITED**

HALL 4.Rossio
16:00 - 17:30

Kidney disease: improving global outcomes - Report on a New International Initiative -

Chair: **G. Eknoyan**, Houston, USA and **N. Lameire**, Ghent, Belgium

Why a global initiative?
G. Eknoyan, Houston, USA

Initial accomplishments: four working groups

- Evidence rating
- CKD evaluation and classification
- Guideline database
- Guideline implementation

N. Lameire, Ghent, Belgium

Global bone and mineral initiative: a bridge to improving healthcare
Outcomes and quality of life
T. Drüeke, Paris, France

Future directions
F. Locatelli, Lecco, Italy

organised by **K/DOQI - NATIONAL KIDNEY FOUNDATION**

HALL 5.Estrela

16:00 - 17:30

When is Fabry nephropathy reversible with enzyme replacement therapy?

Chair: **R. Vanholder**, Ghent, Belgium

Clinical panorama and diagnosis of Fabry disease

A. Mehta, London, United Kingdom

Renal manifestations in Fabry disease

F. Dehout, Charleroi, Belgium

Management of hypertension in Fabry disease

G. Sunder-Plassmann, Vienna, Austria

Clinical achievements with agalsidase alfa enzyme replacement therapy

A. Schwarting, Mainz, Germany

Discussion

organised by **TKT**

Sunday, May 16

MAIN HALL

12:00 - 13:30

Infection and inflammation in dialysis patients

Chair: **E. Ritz**, Heidelberg, Germany

Biofilm - a new perspective in dialysis

W. Costerton, Bozeman, USA

Avoiding bacterial contamination in dialysis fluids

R. Nystrand, Malmö, Sweden

Inflammatory response - mechanisms and consequences

E. Ritz, Heidelberg, Germany

organised by GAMBRO

HALL 1.Alfama

12:00 - 13:30

Renal anaemia, risk factors and beyond – predictors of improved treatment outcomes in patients with CKD

Chair: **F. Locatelli**, Lecco, Italy and **N. Lameire**, Ghent, Belgium

Introduction

F. Locatelli, Lecco, Italy

Diabetes, anaemia and prognosis – can best practice improve outcomes?

N. Lameire, Ghent, Belgium

Cardiovascular risk and CKD – what is the impact of early anaemia treatment?

R. Foley, Minneapolis, USA

Maintaining target Hb levels – the benefits of SC administration

J. Kaufman, Boston, USA

Questions

All

Close

N. Lameire, Ghent, Belgium

organised by **ROCHE**

HALL 2.Baixa
12:00 - 13:30

Shaping the future of phosphate management

Chair: **J. Cannata-Andía**, Oviedo, Spain

Introduction

J. Cannata-Andía, Oviedo, Spain

Clinical practice: are we getting it right?

J. Cannata-Andía, Oviedo, Spain

Lanthanum carbonate: a new solution to an old problem

The biological fate of lanthanum carbonate

S. Damment, Basingstoke, United Kingdom

Lanthanum and bone

M. De Broe, Antwerp, Belgium

Long-term success

A. Hutchison, Manchester, United Kingdom

Moving forward

J. Cunningham, London, United Kingdom

Panel discussion and closing remarks

organised by **SHIRE**

HALL 3.Lapa
12:00 - 13:30

Controversies in iron management

Chair: **I.C. Macdougall**, London, United Kingdom and **D. Van Wyck**, Tucson, USA

Chairman's welcome

I.C. Macdougall, London, United Kingdom

Target ferritin levels in the revised European Best Practice Guidelines on Anaemia Management: are they too high or too low?

D. Richardson, York, United Kingdom

Safety on IV iron preparations:

- are all preparations the same?

- is oxidative stress really a concern?

R.M. Schaefer, Münster, Germany

Can the usage of IV iron in CKD (pre-dialysis) patients avoid / postpone the need for erythropoietic therapy?

D. Silverberg, Tel Aviv, Israel

Discussion – Panel and Audience

Closing remarks

D. Van Wyck, Tucson, USA

organised by **VIFOR**

HALL 4.Rossio

12:00 - 13:30

HDF Buffer Management

Chair: **R. Vanholder**, Ghent, Belgium and **A. Santoro**, Bologna, Italy

HDF: the European perspective

A.L.M. de Francisco, Santander, Spain

HDF on-line: clinical and technical overview

R. Greenwood, Stevenage, United Kingdom

Acetate Free: does acetate really matter?

B. Perrone, Pontoise, France

Biocompatibility of dialysate buffers

R. Coppo, Turin, Italy

Acetate free on-line hemodiafiltration: first clinical experience

F. Pizzarelli, Florence, Italy

organised by **BELLCO**

HALL 5.Estrela

12:00 - 13:30

New options in optimising long-term outcomes after 10 years of tacrolimus

Chair: **J.L. Reimao Pinto**, Lisbon, Portugal

Introductory remarks

J.L. Reimao Pinto, Lisbon, Portugal

Confronting chronic graft nephropathy

K. Baboolal, Cardiff, UK

PTDM in perspective

J.P. van Hooff, Maastricht, The Netherlands

Corticosteroid-sparing strategies with tacrolimus

J.M. Campistol, Barcelona, Spain

Discussion

Concluding remarks

J.L. Reimao Pinto, Lisbon, Portugal

organised by **FUJISAWA**

Monday, May 17

MAIN HALL

12:00 - 13:30

Intervention in the progression and consequences of Chronic Kidney Disease

Chair: **J. Frazão**, Porto, Portugal

Inflammation, oxidative stress and vascular calcification in CKD - are they partners in crime?

P. Stenvinkel, Stockholm, Sweden

Prevention of vascular diseases through improved management of bone and mineral disorders in CKD patients

T. Drüeke, Paris, France

Prevention of progression of Fabry disease in renal patients

B. Cianciaruso, Naples, Italy

organised by **GENZYME**

HALL 1.Alfama

12:00 - 13:30

In the focus: heart and vessels in chronic kidney disease

Chair: **F. Locatelli**, Lecco, Italy

Cardiovascular risk factors - a challenge from the start of dialysis

Data from the MPO study

F. Locatelli, Lecco, Italy

Vascular stiffening – cardiovascular mortality

How can we break the link?

D. Goldsmith, London, United Kingdom

Management of increased atherogenicity in uraemia

C. Wanner, Würzburg, Germany

organised by **FRESENIUS MEDICAL CARE**

HALL 3.Lapa
12:00 - 13:30

Pursuing better outcomes in chronic kidney disease patients

Chair: **F. Carrera**, Lisbon, Portugal

Introduction

F. Carrera, Lisbon, Portugal

Anaemia: a key mortality risk factor in chronic kidney disease patients

B. Pereira, Boston, USA

Extending the dosing intervals for anaemia patients

Y. Vanrenterghem, Leuven, Brussels

Assessing control of secondary hyperparathyroidism in Europe

J. Cannata-Andía, Oviedo, Spain

The value of bringing patients with secondary hyperparathyroidism to target

J. Cunningham, London, United Kingdom

organised by **AMGEN**

HALL 4.Rossio
12:00 - 13:30

Advances in Vitamin D Therapy

Chair: **J. Cannata-Andía**, Oviedo, Spain

Welcome and Introduction

J. Cannata-Andía, Oviedo, Spain

Overview of Vitamin D analogs

E. Slatopolsky, St. Louis, USA

Vitamin D analogs and the treatment of Secondary Hyperparathyroidism

S. Sprague, Evanston, USA

Cardiovascular effects of Vitamin D

G. London, Fleury Merogis, France

Vitamin D and the prevention of morbidity and mortality

R.I. Thadhani, Boston, USA

Panel Discussion

organised by **ABBOTT**

HALL 5.Estrela
12:00 - 13:30

Unpredicted events in dialysis: inflammation, oxidation, and endothelial changes - culprits or targets

Chair: **E. Ritz**, Heidelberg, Germany

Inflammation
E. Ritz, Heidelberg, Germany

Oxidation
G. Pertosa, Bari, Italy

Endothelial Changes
M. Bonomini, Chieti, Italy

organised by **KURARAY**